Development of a clinically viable MRGPRX4 inverse agonist for cholestatic itch treatment.

HEP-50768, a potent and selective inverse agonist of MRGPRX4, suppresses bile-acid-induced pruritic behaviors in humanized rats, indicating its potential for cholestatic itch treatment.

• Why it matters: Chronic itch in cholestatic conditions significantly impacts patient quality of life, and current treatments are inadequate. Targeting MRGPRX4 offers a promising new approach to address this unmet need.
• What they did: Researchers identified and optimized HEP-50768 through high-throughput screening and structural studies, then demonstrated its efficacy in suppressing pruritic behaviors in humanized rat models, alongside safety profiling in rats and monkeys.
• The result: Findings support HEP-50768 as a promising therapeutic candidate for chronic itch, enabling its progression to clinical evaluation for cholestatic pruritus.